Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug vedotin + immune checkpoint inhibitor + gemcitabine for EGFR-positive locally advanced pancreatic cancer
ChiCTR2600129066Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of becotatug vedotin in pancreatic adenocarcinoma (PDAC), sponsored by Huashan Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600129066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129066.